CD47/SIRPα Axis Blockade Emerges as Promising, Complex Target for Cancer Immunotherapy
Background
The CD47/SIRPα axis is a critical innate immune checkpoint that allows cancer cells to evade macrophage-mediated phagocytosis, acting as a 'don't eat me' signal. While therapeutic blockade of this pathway offers significant potential for cancer immunotherapy, current strategies face a major hurdle: achieving potent antitumor effects without inducing severe on-target hematotoxicity, particularly anemia. Understanding the intricate biology of CD47 and developing highly selective targeting agents are crucial to unlock its full therapeutic promise and overcome these clinical limitations.
Study Design
This comprehensive review synthesizes recent advances in CD47 biology, including its transcriptional and post-translational regulation, and its crosstalk with other signaling pathways. It evaluates innovative therapeutic strategies for safely targeting this innate immune checkpoint, discussing emerging evidence that CD47 functions beyond its canonical role as a phagocytosis checkpoint. The review also covers the development of next-generation CD47-targeting agents, such as tumor-selective bispecific antibodies and peptide inhibitors, alongside combination regimens designed to maximize therapeutic efficacy while minimizing systemic toxicity.
Results
The CD47/SIRPα axis is confirmed as a pivotal 'don't eat me' signaling pathway, enabling tumor immune evasion by inhibiting macrophage-mediated phagocytosis. Therapeutic blockade of this axis holds significant promise for cancer immunotherapy, yet achieving an optimal balance between antitumor efficacy and on-target hematotoxicity, specifically anemia, remains a major clinical challenge. The review highlights that CD47's functions extend beyond its canonical role as a phagocytosis checkpoint, encompassing roles in regulating the tumor microenvironment and contributing to T-cell dysfunction.
Emerging therapeutic strategies focus on developing next-generation CD47-targeting agents, including tumor-selective bispecific antibodies and novel peptide inhibitors, to enhance efficacy while mitigating systemic toxicity. Furthermore, combination regimens are being explored to synergize with other immunotherapies and overcome resistance mechanisms, aiming for more durable and safer clinical responses.
Key Findings
- The CD47/SIRPα axis is a critical 'don't eat me' signal for tumor immune evasion.
- Therapeutic blockade of CD47 shows promise but is limited by on-target hematotoxicity, especially anemia.
- CD47's roles extend beyond phagocytosis, influencing the
tumor microenvironmentandT-cell dysfunction. - Next-generation CD47-targeting agents (e.g., bispecific antibodies, peptide inhibitors) aim for tumor selectivity.
- Combination regimens are being developed to maximize efficacy and minimize systemic toxicity.
Why It Matters
This review underscores that targeting the CD47/SIRPα axis represents a powerful, yet complex, strategy for cancer immunotherapy. For clinicians and researchers, it highlights the critical need for tumor-selective CD47 inhibitors that can effectively unleash macrophage activity without causing severe anemia. The discussion of next-generation agents, such as bispecific antibodies and peptide inhibitors, suggests future protocols will likely involve more nuanced, targeted approaches. Combining CD47 blockade with other immunotherapies or chemotherapy could become a standard practice, potentially overcoming current limitations and expanding treatment options for various cancers. This shift towards precision targeting could significantly improve patient outcomes and tolerability.
cd47
sirpa
cancer-immunotherapy
immune-checkpoint
macrophage
tumor-microenvironment